This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01155/identifier/chebi/
n25http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB01155/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01155/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n18http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01155/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01155/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01155/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01155
rdf:type
n3:Drug
n3:description
Gemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
n3:dosage
n24:271B4AAE-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
7 (± 2) hours
n3:indication
For the treatment of bacterial infection caused by susceptible strains such as <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>H. parainfluenzae</i>, or <i>M. catarrhalis</i>, <i>S. pneumoniae</i> (including multi-drug resistant strains [MDRSP]), <i>M. pneumoniae</i>, <i>C. pneumoniae</i>, or <i>K. pneumoniae</i>.
owl:sameAs
n23:DB01155 n25:DB01155
dcterms:title
Gemifloxacin
adms:identifier
n13:PA10088 n14:D02471 n15:67707-320-05 n16:101853 n19:DB01155 n26:Gemifloxacin
n3:mechanismOfAction
The bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
n3:packager
n11:271B4AA9-363D-11E5-9242-09173F13E4C5 n11:271B4AAA-363D-11E5-9242-09173F13E4C5 n11:271B4AAB-363D-11E5-9242-09173F13E4C5
n3:patent
n8:6262071 n8:5633262
n3:routeOfElimination
Gemifloxacin and its metabolites are excreted via dual routes of excretion.Following oral administration of gemifloxacin to healthy subjects, a mean (± SD) of 61 ± 9.5% of the dose was excreted in the feces and 36 ± 9.3% in the urine as unchanged drug and metabolites. The mean (± SD) renal clearance following repeat doses of 320 mg was approximately 11.6 ± 3.9 L/hr (range 4.6-6 L/hr), which indicates active secretion is involved in the renal excretion of gemifloxacin.
n3:synonym
Gemifloxacin mesilate gemifloxacin mesylate Factiv
n3:volumeOfDistribution
* 1.66 to 12.12 L/kg
n9:hasAHFSCode
n28:08-12-18
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
60-70%
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Gemifloxacin.htm
n5:hasConcept
n6:M0370050
foaf:page
n18:fac1662.shtml n20:gemifloxacin.html n21:factive.htm
n3:IUPAC-Name
n4:271B4AB3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4AB9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4AB8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4AB5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4AB6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4AB7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4AC9-363D-11E5-9242-09173F13E4C5 n4:271B4AB1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4ACA-363D-11E5-9242-09173F13E4C5 n4:271B4AAF-363D-11E5-9242-09173F13E4C5 n4:271B4AB2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4AB0-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:J01MA15
n3:H-Bond-Acceptor-Count
n4:271B4ABF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4AC0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4ABA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4ABB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4ABD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4ABC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4ABE-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed from the gastrointestinal tract. The absolute bioavailability averages approximately 71%.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
175463-14-6
n3:category
n3:clearance
* renal cl=11.6+/- 3.9 L/hr [Healthy subjects receiving repeat doses of 320 mg orally]
n3:containedIn
n7:271B4AAD-363D-11E5-9242-09173F13E4C5 n7:271B4AAC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4AC5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4AC7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4AC8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4AC4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4AC3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4AC6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4AB4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4AC1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4AC2-363D-11E5-9242-09173F13E4C5